aspirin plus extended-release dipyridamole (25 mg/200mg twice daily)
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2008 Sep 18;359(12):1238-51 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, thrombotic The Use of
aspirin plus extended-release dipyridamole (25 mg/200mg twice daily)
As Prevention, Secondary
Is worse Than
clopidrogel (75 mg once daily)
To reduce at 2.5 years recurrent ischemic stroke (9% aspirin VS 8.8% clopid) or cardiovascular events (13.1% both groups) and there were more haemorrhagic events (4.1% aspirin VS 3.6% clopid)